Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31310684 | 0.86 | LMNA (0.53) | LMNACYP2D6ADRB2ADRB1ADRB3 | |
| SCHEMBL1001111 | 0.84 | LMNA (0.72) | LMNACYP2D6ADRB2ADRB1ADRB3 | |
| SCHEMBL970564 | 0.84 | LMNA (0.72) | LMNACYP2D6ADRB2ADRB1ADRB3 | |
| SCHEMBL28259807 | 0.84 | LMNA (0.85) | LMNACYP2D6ADRB2ADRB1ADRB3 | |
| Diphenylether SCHEMBL27791740 | 0.83 | LTA4H (0.42) | LMNACYP1A2CYP2C19 | |
| SCHEMBL872625 | 0.82 | LMNA (0.75) | LMNACYP2D6ADRB2ADRB1ADRB3 | |
| Methoxymethane SCHEMBL9729148 | 0.81 | LMNA (0.92) | LMNACYP2D6ADRB2ADRB1ADRB3 | |
| SCHEMBL3254859 | 0.80 | LMNA (1.00) | LMNACYP2D6ADRB2ADRB1ADRB3 | |
| SCHEMBL2943775 | 0.80 | LMNA (1.00) | LMNACYP2D6ADRB2ADRB1ADRB3 | |
| SCHEMBL50453 | 0.80 | LMNA (1.00) | LMNACYP2D6ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 650 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3976362-B1 | METHOD FOR MAKING OPAQUE COLORED SILICONE HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2023-06-07 | — | — | EP | claimed |
| US-11584097-B2 | Method for making opaque colored silicone hydrogel contact lenses | ALCON INC. (CH) | 2023-02-21 | — | — | US | claimed |
| WO-2020240440-A1 | METHOD FOR MAKING OPAQUE COLORED SILICONE HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2020-12-03 | — | — | WO | claimed |
| US-20200376787-A1 | METHOD FOR MAKING OPAQUE COLORED SILICONE HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2020-12-03 | — | — | US | claimed |
| US-9244195-B2 | Silicone hydrogel lenses with nano-textured surfaces | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | claimed |
| EP-2718751-B1 | SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES | NOVARTIS AG (CH) | 2015-07-22 | — | — | EP | claimed |
| EP-2718751-A1 | SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES | Novartis AG (CH) | 2014-04-16 | — | — | EP | claimed |
| US-8506856-B2 | Method for making silicone hydrogel contact lenses | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | claimed |
| WO-2012170603-A1 | SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES | NOVARTIS AG (CH) | 2012-12-13 | — | — | WO | claimed |
| US-20120314185-A1 | SILICONE HYDROGEL LENSES WITH NANO-TEXTURED SURFACES | ALCON INC. (CH) | 2012-12-13 | — | — | US | claimed |
| CN-101896837-A | Method of making silicone hydrogel contact lenses | NOVARTIS AG | 2010-11-24 | — | — | CN | claimed |
| EP-2232304-A2 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | Novartis AG (CH) | 2010-09-29 | — | — | EP | claimed |
| WO-2009076143-A2 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | claimed |
| US-20090146330-A1 | METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES | ALCON INC. (CH) | 2009-06-11 | — | — | US | claimed |
| EP-4121802-B1 | HIGH REFRACTIVE INDEX SILOXANE INSERT MATERIALS FOR EMBEDDED CONTACT LENSES | ALCON INC (CH) | 2024-07-17 | — | — | EP | disclosed |
| EP-4121279-B1 | METHOD FOR PRODUCING EMBEDDED OR HYBRID HYDROGEL CONTACT LENSES | ALCON INC (CH) | 2024-07-10 | — | — | EP | disclosed |
| EP-3724696-B1 | WEEKLY AND MONTHLY DISPOSABLE WATER GRADIENT CONTACT LENSES | ALCON INC (CH) | 2024-07-03 | — | — | EP | disclosed |
| US-20030125498-A1 | Biomedical devices containing internal wetting agents | JOHNSON & JOHNSON VISION CARE, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2003022322-A2 | BIOMEDICAL DEVICES CONTAINING INTERNAL WETTING AGENTS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
| WO-2003022321-A2 | BIOMEDICAL DEVICES CONTAINING INTERNAL WETTING AGENTS | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584097-B2 | Method for making opaque colored silicone hydrogel contact lenses | COIL, CRYAB, CRYAA | LMNA 613/4885CYP2D6 2696/4885ADRB2 4741/4885 |
| US-20200376787-A1 | METHOD FOR MAKING OPAQUE COLORED SILICONE HYDROGEL CONTACT LENSES | COIL, CRYAB, CRYAA | LMNA 613/4885CYP2D6 2696/4885ADRB2 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.